A study published by the Journal of Investigative Dermatology has revealed promising results for a new vaccine that could prevent acne vulgaris.
The study suggests that propionibacterium acnes, an opportunistic skin bacterium, has been linked to the cause of acne vulgaris. It details that a vaccine could block this bacteria by producing an inflammation-triggering toxin called christie-atkins-munch-petersen (CAMP).
Lead researcher, Dr Chun-Ming Huang stated, “Once validated by a large-scale clinical trial, the potential impact of our findings is huge for the hundreds of millions of individuals suffering from acne vulgaris.”
He added, “Current treatment options are often not effective or tolerable for many of the 85% of adolescents and more than 40 million adults in the US who suffer from this multi-factorial cutaneous inflammatory condition. New, safe, and efficient therapies are sorely needed."
The study has only been held on mice and skin cells at present, and the next stage is for it to be tested in a large-scale clinical trial on humans.
However, dermatologist Dr Rikin Parekh, believes the vaccine won’t be enough to combat this common skin condition.
“I can’t see it being a totally effective way to cure every person’s acne; however, it is an interesting concept but one that would need to be trialled and tested before being used on patients. The vaccination may also include mild to severe side effects depending on the patient, so this should also be noted.”
He added, “Furthermore, everyone’s epidermis is different so a ‘one vaccination fits all’ ideal may not be completely successful. Ultimately, a good skincare regime tailored to a patient’s skin type using an appropriate cleanser, exfoliative and a toner which reduces sebum will help reduce and prevent acne from forming.”